Skip to content

IEMbase 0152: UMPS-related hereditary orotic aciduria

Scope

Field Value
IEMbase ID 152
Nosology 16.1.03.01
Gene UMPS
External IDs OMIM:258900; ORPHA:30
Generated mapping MAPPED to Hereditary_Orotic_Aciduria.yaml
Candidate DisMech targets Hereditary_Orotic_Aciduria.yaml
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents this as UMPS-related uridine monophosphate synthase deficiency, with alternate labels hereditary orotic aciduria and orotate phosphoribosyltransferase deficiency. Treatability is marked yes.

The biochemical rows include decreased red-cell UMPS/OPRT activity, increased plasma orotic acid, markedly increased urinary orotic acid, and reticulocyte abnormality. Clinical rows include megaloblastic anemia, hypochromia, anisocytosis, poikilocytosis, developmental delay, failure to thrive, diarrhea, T-cell immunodeficiency, recurrent infections, hematuria, and urolithiasis.

DisMech phenotype coverage

Hereditary_Orotic_Aciduria.yaml is the correct target. It models biallelic UMPS loss of function, deficient orotate phosphoribosyltransferase and/or OMP decarboxylase activity, impaired de novo UMP synthesis, massive urinary orotic acid overexcretion, megaloblastic anemia, global developmental delay, failure to thrive, T-cell immunodeficiency, recurrent respiratory infections, orotic acid crystalluria, and uridine triacetate therapy.

Concordance and completeness

Judgement: correct mapping with high concordance.

The IEMbase and DisMech profiles agree on UMPS, orotic acid accumulation, megaloblastic anemia, developmental delay, failure to thrive, T-cell immunodeficiency, recurrent infection, and treatment by uridine replacement. IEMbase adds plasma orotic acid and selected hematologic smear terms, plus hematuria/urolithiasis wording that could be reviewed against the local crystalluria-focused renal phenotype.

Curation actions

  • Keep the mapping to Hereditary_Orotic_Aciduria.yaml.
  • Consider future biomarker refinement for plasma orotic acid and explicit red-cell UMPS/OPRT activity.
  • Review whether IEMbase hematuria/urolithiasis should be represented locally as downstream consequences of orotic acid crystalluria or left as unconfirmed IEMbase-only clinical rows.